Daclizumab has poor efficacy in steroid-refractory severe acute graft-versus-host disease: a single centre experience with 12 allograft patients.

Hui, C H; Sia, H; Mangos, H; Horvath, N; Lee, H; Lewis, I; Hughes, T; To, L B; Bardy, P

Hui, C H; Sia, H; Mangos, H; Horvath, N; Lee, H; Lewis, I; Hughes, T; To, L B; Bardy, P.

Bone Marrow Transplant ; 41(4): 409-10, 2008 Feb.

Article in En | MEDLINE | ID: mdl-18026147

Subject(s)

Antibodies, Monoclonal/adverse effects; Graft vs Host Disease/drug therapy; Hematopoietic Stem Cell Transplantation/adverse effects; Immunoglobulin G/adverse effects; Immunosuppressive Agents/adverse effects; Adult; Antibodies, Monoclonal, Humanized; Daclizumab; Female; Humans; Male; Medical Audit; Methylprednisolone/therapeutic use; Middle Aged; Retrospective Studies; Salvage Therapy; Transplantation, Homologous/adverse effects; Treatment Failure

Search on Google

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Immunoglobulin G / Hematopoietic Stem Cell Transplantation / Graft vs Host Disease / Immunosuppressive Agents / Antibodies, Monoclonal Type of study: Observational_studies Limits: Adult / Female / Humans / Male / Middle aged Language: En Journal: Bone Marrow Transplant Year: 2008 Document type: Article

Search on Google

XML

PubMed Links